EmeraNova™ Adds Hyaluronic Acid Matrix Technology, Supporting Expansion to New Care Settings

Hyalomatrix® Joins EmeraNova's Toolbox of Tissue Restoration Technologies

PHOENIX--(BUSINESS WIRE)--EmeraNova^TM, the new corporate identity of BioLab Holdings and a medical technology company building an advanced tissue restoration platform, is expanding its tissue preparation and restorative capabilities through a new commercialization collaboration with Hyalomatrix®.

Hyalomatrix is a regenerative matrix built on hyaluronic acid technology to support tissue regeneration and complex wound healing. The technology joins EmeraNova’s growing toolbox of solutions designed to help clinicians address tissue loss, prepare wound beds and support healing across a wide range of care settings.

The addition of Hyalomatrix further strengthens EmeraNova's commitment to building one of the industry's most comprehensive platforms of tissue restoration technologies, by working together with innovative companies developing advanced regenerative, diagnostic and therapeutic solutions.

"What makes Hyalomatrix so exciting is that it’s a well-established technology backed by years of clinical experience," said EmeraNova President & CEO Jaime Leija. "With its foundation in hyaluronic acid, a natural component of healthy skin, Hyalomatrix provides clinicians with another robust option for managing both acute and chronic wounds. Through our collaboration, we're helping bring renewed attention to a trusted regenerative solution and expanding access to a technology that deserves a place in more care settings.”

The technology is indicated for a broad range of applications, including surgical wounds, trauma wounds, partial- and full-thickness wounds, partial thickness second-degree burns, chronic vascular ulcers, diabetic ulcers, pressure ulcers and tunneling wounds. Its versatility allows clinicians to utilize the product across multiple specialties where effective tissue regeneration is critical.

"We're proud to partner with EmeraNova at a time when tissue restoration is evolving so rapidly," said Andrew Dunn, CEO of Halo Biosystems. “They’ve created a unique platform that brings together innovative technologies under a shared commitment to advancing patient care. Hyalomatrix is backed by clinical data and 22 peer-reviewed publications, and we’re excited to bring solutions to more clinicians than ever before.”

The collaboration reflects EmeraNova's continued strategy of identifying and commercializing technologies that complement its tissue restoration platform. Through its national commercialization network, EmeraNova will support broader access to Hyalomatrix across mobile and outpatient wound care centers, hospitals, ambulatory surgery centers and other sites of care nationwide.

For more information on EmeraNova's toolbox of tissue restoration products, visit emeranova.com.

About EmeraNova™

EmeraNova™ is a leading medical technology company advancing tissue restoration across healing phases, care settings, and specialties by building a global platform that identifies promising technologies from around the world and accelerates their path into clinical practice. Through an expanding toolbox of tissue restoration solutions, world-class support, and a commitment to bringing together expert voices and clinical insights, EmeraNova aims to help shape what’s possible in tissue repair. BLS Labs, LLC and BLS Sales & Marketing, LLC, are accredited by the Association for Advancing Tissue and Biologics (AATB), reflecting the organization’s commitment to rigorous standards for quality, safety and operational excellence. For more information, visit emeranova.com.